Category - Developments

Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...

September 28, 2023

Developments

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...

September 25, 2023

Developments

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

iBio (NYSEA:IBIO) announced a sixth amendment to its credit agreement with Woodforest National bank to allow sufficient time for the company to complete the pending sale of its cGMP biologics manufacturing facility. The...

September 22, 2023

Developments

IntelGenx receives first RIZAFILM purchase order from U.S. partner Gensco

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that it received the first purchase order (PO) for RIZAFILM from its U.S. commercial partner, Gensco Pharma. The company expects to ship the order to Gensco in the first quarter...

September 21, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that rencofilstat demonstrated anti-cancer activity across 86% of cancer types in a high-throughput screen on 850 cancer cell lines. At the Broad Institute of MIT and...

September 21, 2023

Developments

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx’s (TSX:IGX; OTCQB:IGXT) buprenorphine buccal film – for which an amendment to the abbreviated to new drug application (ANDA) requesting priority review has been filed by Chemo Research through its agent and...

September 20, 2023

Developments

Hepion discovers novel rencofilstat action in liver cancer

Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...

September 20, 2023

Developments

Anixa forms cancer business advisory board

Anixa Biosciences (NASDAQ:ANIX) formed a cancer business advisory board (CBAB) with a roster of renowned cancer advocates, executives and physicians to guide the company’s clinical and business development...

September 19, 2023

Developments

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Closely-held Mati Therapeutics completed a dedicated manufacturing facility for products formulated using the company’s Evolute sustained ocular drug delivery platform. Mati expects that the 10,000-square-foot facility...

September 15, 2023

Developments

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...

September 14, 2023

Category - Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

IntelGenx receives first RIZAFILM purchase order from U.S. partner Gensco

Hepion’s rencofilstat demonstrates anti-cancer activity

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

Hepion discovers novel rencofilstat action in liver cancer

Anixa forms cancer business advisory board

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

General

More